Colorectal Cancer

Studies have increasingly supported the use of total neoadjuvant therapy, moving chemotherapy use ahead of surgical resection of rectal tumors.

The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.

The FDA plans to conduct a speedy review of an approval application for trifluridine plus tipiracil and bevacizumab for the treatment of metastatic colorectal cancer.

In an interview with Targeted Oncology, Olumide B. Gbolahan, MBBS, MSc, commented on studies that support the use of ctDNA to guide treatment decisions in the adjuvant setting for patients with colorectal cancer.

Neither the LEAP-003 nor LEAP-017 studies study showed survival benefit with pembrolizumab plus lenvatinib for patients with melanoma or colorectal cancer.

Soon, the FDA will be considering fruquintinib for approval to treat patients with refractory metastatic colorectal cancer.

The rise of earlier-onset disease and the introduction of noninvasive testing has changed the landscape of colorectal cancers for oncologists.

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.

Pixatimod and nivolumab showed benefits for patients with microsatellite-stable metastatic colorectal cancer.

In the wave of its major influence on these malignancies, anti-HER2 therapy for various cancers—notably colorectal cancer —has been thoroughly investigated.

Encouraging results in melanoma have led experts to explore the gut microbiome in colorectal cancer.  The next hot topic in research may be the gut microbiome's role for the prevention, progression, and management of colorectal cancer.

In an interview with Targeted Oncology, John Strickler, MD, discussed the background and goals of the DeFianCe study in the colorectal cancer space.

Despite achieving the co-primary end points, the phase 3 PRESERVE trial of trilaciclib in patients with metastatic colorectal cancer will be terminated.

Results of a study of dabrefenib, trametinib, and spartalizumab showed efficacy for the combination of a BRAF inhibitor, a MEK inhibitor, and an anti–PD-1 agent in patients with BRAF V600-mutated colorectal cancer.

In an interview with Targeted Oncology, Benjamin Schlechter, MD, FACS, discussed the background of a phase 1a/1b trial in microsatellite stable colorectal cancer and how these findings will influence future research.

Results from the CRC-PREVENT trial of a noninvasive diagnostic screening test have led to the submission of a premarket approval application to the FDA for patients with colorectal cancer and advanced adenomas.

Tanios Bekaii-Saab, MD, FACP, discusses background that led to the start of the MOUNTAINEER-03 trial.

In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, FACP, discussed the methods and design of the MOUNTAINEER-03 trial and its role following the positive data observed from MOUNTAINEER.

Breast and gastric cancer algorithms are acceptable to use when identifying patients with colorectal cancer who may respond to tucatinib in combination with trastuzumab.

According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.

Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.

The combination use of encorafenib plus cetuximab and chemotherapy appeared to be safe and effective in treating patients with BRAF V600E-mutant metastatic colorectal cancer.

The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.

Tanios S. Bekaii-Saab, MD, FACP, discusses what to expect if data from the MOUNTAINEER-03 study are positive.

MOUNTAINEER study results have wowed the FDA, leading to an accelerated FDA approval of tucatinib plus trastuzumab as RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer treatment.